Press Releases
Agreement with a360 Media Delivers Phexxi Branded Content in Leading Entertainment and Lifestyle Magazines
a360 Media's Brands Include US Magazine, InTouch Weekly, and Woman's World
16% Lift in New Phexxi Prescriptions After First Two Weeks of Partnership
SAN DIEGO, July 21, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced an agreement between Evofem and a360 Media under which Phexxi® (lactic acid, citric acid, and potassium bitartrate) branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S.
"We are thrilled to partner with a360 Media to raise awareness of Phexxi among the millions of women reading some of the most popular magazines and websites in America," said Saundra Pelletier, Chief Executive Officer of Evofem.
a360 Media reaches 60 million unique digital visitors per month and another 27 million via print audiences. One out of every three a360 Media readers and digital users is a female between the ages of 18 and 34, making this partnership an ideal union. To date, 72% of the prescriptions through the Phexxi telehealth program are to women in this demographic.
After the first two weeks of the partnership, new prescriptions of Phexxi - a hormone-free, on-demand prescription contraceptive vaginal gel - were up 16%.
"Our magazine and digital brands are geared towards women looking for the latest on current events and information that can help them better their health and relationships," said Neil Goldstein, a360 Media's EVP, Chief Revenue Officer. "We are pleased to partner with Evofem to boost Phexxi's visibility with our readers, especially those women seeking hormone-free contraception, or those who are tired of the side effects they may be suffering from hormonal methods."
Three popular magazines featuring Phexxi content are on newsstands now, with more to come during the next several months.
About Evofem Biosciences
Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, evaluations and judgments regarding Evofem, its products, its product candidates and their development, demand for Evofem's products and product candidates, and the effectiveness or implied effectiveness of Evofem's efforts with a360 Media. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward- looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022 and its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
Media Contact
media@evofem.com
SOURCE Evofem Biosciences, Inc.
